Supernus Pharmaceuticals
SUPN
43.05
+0.22
+0.51%
Supernus Pharmaceuticals
US · SUPN
#2636 by market cap
Listed 1970
43.05
+0.22
+0.51%
Live - 5344 symbols - heartbeat 30s ago
· 2026-10-08 04:02
Pre-market
42.45
-1.39%
After-hours
43.05
0.00%
- Market cap
- 2.51B
- P/E (TTM)i
- -22.42
- P/Bi
- 2.43
- EPSi
- -0.68
- Div yieldi
- 0.00%
- 52W posi
- 13%
Reader sentiment
Are you bullish or bearish on SUPN?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 4 analysts
Buy
Avg price target
65.25 +51.6%
Price target rangecurrent 43.05
Low63.00
Avg65.25
High67.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-08-03 | TD Cowen | -- | BUY | 65.00 |
| 2026-07-27 | Piper Sandler | -- | BUY | 66.00 |
| 2026-07-13 | BofA Securities | -- | BUY | 63.00 |
| 2026-07-09 | Cantor Fitzgerald | -- | BUY | 67.00 |
| 2026-06-04 | Piper Sandler | -- | BUY | 66.00 |
| 2026-05-06 | Piper Sandler | -- | BUY | 66.00 |
| 2026-05-06 | Stifel | -- | HOLD | 55.00 |
| 2026-05-05 | TD Cowen | -- | BUY | 65.00 |
| 2026-04-27 | Piper Sandler | -- | BUY | 66.00 |
| 2026-04-23 | TD Cowen | -- | BUY | 65.00 |
| 2026-04-13 | Piper Sandler | -- | BUY | 66.00 |
| 2026-02-25 | TD Cowen | -- | BUY | 65.00 |
| 2026-02-25 | Stifel | -- | HOLD | 55.00 |
| 2026-02-24 | TD Cowen | -- | BUY | 65.00 |
| 2026-02-24 | Cantor Fitzgerald | -- | BUY | 63.00 |
| 2026-02-24 | BofA Securities | -- | BUY | 65.00 |
| 2026-02-06 | BofA Securities | -- | BUY | 65.00 |
| 2026-01-28 | Piper Sandler | -- | BUY | 65.00 |
| 2026-01-20 | BofA Securities | -- | BUY | 65.00 |
| 2026-01-09 | Piper Sandler | -- | BUY | 65.00 |
| 2026-01-08 | Cantor Fitzgerald | -- | BUY | 63.00 |
| 2026-01-07 | BofA Securities | -- | BUY | 65.00 |
| 2025-12-19 | Stifel | -- | HOLD | 55.00 |
| 2025-12-17 | BofA Securities | -- | BUY | 65.00 |
| 2025-11-05 | BofA Securities | -- | BUY | 65.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
C
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-04 | After close | ±11.59% | +8.46% (in line) |
| 2026/Q1 | 2026-05-05 | After close | ±12.36% | +4.59% (in line) |
| 2025/Q4 | 2026-02-24 | After close | ±13.52% | +5.67% (in line) |
| 2025/Q3 | 2025-11-04 | After close | ±11.23% | -17.35% (beat) |
| 2025/Q2 | 2025-08-05 | After close | -- | +13.08% |
| 2025/Q1 | 2025-05-06 | After close | ±12.30% | -4.59% (in line) |
| 2024/Q4 | 2025-02-25 | After close | ±8.52% | -2.74% (in line) |
| 2024/Q3 | 2024-11-04 | After close | ±10.88% | +0.12% (in line) |
| 2024/Q2 | 2024-08-06 | After close | ±10.67% | +14.49% (beat) |
| 2024/Q1 | 2024-05-08 | After close | ±11.47% | -4.15% (in line) |
| 2023/Q4 | 2024-02-27 | After close | ±20.19% | +1.27% (in line) |
| 2023/Q3 | 2023-11-08 | After close | ±10.63% | +11.14% (beat) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 04:02:46 · For reference only, not investment advice and not tailored to your situation.